Promise Bio, a startup transforming immune-mediated disease treatment with advanced precision medicine solutions, today announced its emergence from stealth with an $8.3 million seed investment. This funding will accelerate the development of Promise Bio’s computational platform, which uses epiproteomics and artificial intelligence to predict patient treatment responses and support drug research and development. “Current biological treatments for autoimmune diseases don’t work in all patients, with only 30-40% of patients achieving significant remission. At Promise Bio, our mission...